In summary, the deletion of systemic or non‐BM CD34+ cells, but not BM CD34+ cells, exacerbates AAA progression and increases animal mortality, supporting the beneficial effect of these CD34+ cells in restricting and stabilizing AAA. This evidence concerns the gene CD34 and triple-A syndrome.